These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 2866620)

  • 21. Sodium pentosan polysulphate--a novel inhibitor of urinary risk factors and enzymes in experimental urolithiatic rats.
    Senthil D; Malini MM; Varalakshmi P
    Ren Fail; 1998 Jul; 20(4):573-80. PubMed ID: 9713875
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Determination of the calcium oxalate crystallization risk from urine samples: the BONN Risk Index in comparison to other risk formulas.
    Laube N; Hergarten S; Hoppe B; Schmidt M; Hesse A
    J Urol; 2004 Jul; 172(1):355-9. PubMed ID: 15201810
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Basic studies of citrate therapy on urolithiasis--the effect of citrate on solubility of calcium oxalate crystal and on calcium deposition of murine kidney in experimental oxalate stone].
    Yasukawa S
    Nihon Hinyokika Gakkai Zasshi; 1988 Apr; 79(4):613-9. PubMed ID: 3226013
    [No Abstract]   [Full Text] [Related]  

  • 24. Inhibitors of oxalocalcic lithiasis: effects of their interactions on calcium oxalate crystallization.
    Muñoz JA; López-Mesas M; Valiente M
    Urology; 2012 Nov; 80(5):1163.e13-8. PubMed ID: 22748613
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Calcium oxalate stone formation risk - a case of disturbed relative concentrations of urinary components.
    Laube N; Rodgers A; Allie-Hamdulay S; Straub M
    Clin Chem Lab Med; 2008; 46(8):1134-9. PubMed ID: 18578688
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibitors of stone formation.
    Worcester EM
    Semin Nephrol; 1996 Sep; 16(5):474-86. PubMed ID: 8890402
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative study of the effects of pyruvate and CG-120 in preventing experimental oxalate urolithiasis in rats.
    Ogawa Y; Yamaguchi K; Tanaka T; Morozumi M
    Hinyokika Kiyo; 1986 Sep; 32(9):1341-7. PubMed ID: 3812152
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Hyperuricosuria and urolithiasis].
    Koide T
    Nihon Rinsho; 1996 Dec; 54(12):3273-6. PubMed ID: 8976104
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of the relative inhibitory potential of fractionated urinary macromolecules.
    Azoury R; Goldwasser B; Wax Y; Perlberg S; Garti N; Sarig S
    Urol Res; 1985; 13(4):199-205. PubMed ID: 4049608
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The amino acid factor in stone formers' and normal urines.
    Azoury R; Garti N; Sarig S
    Urol Res; 1986; 14(6):295-8. PubMed ID: 3544447
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intestinal Oxalobacter formigenes colonization in calcium oxalate stone formers and its relation to urinary oxalate.
    Troxel SA; Sidhu H; Kaul P; Low RK
    J Endourol; 2003 Apr; 17(3):173-6. PubMed ID: 12803990
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Uric acid: an abettor or protector in calcium oxalate urolithiasis? Biochemical study in stone formers.
    Srinivasan S; Kalaiselvi P; Sakthivel R; Pragasam V; Muthu V; Varalakshmi P
    Clin Chim Acta; 2005 Mar; 353(1-2):45-51. PubMed ID: 15698589
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of overweight and obesity in calcium oxalate stone formation.
    Siener R; Glatz S; Nicolay C; Hesse A
    Obes Res; 2004 Jan; 12(1):106-13. PubMed ID: 14742848
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Studies on urolithiasis: crystal aggregation in calcium oxalate stone formers (author's transl)].
    Suzuki K
    Nihon Hinyokika Gakkai Zasshi; 1981 Jul; 72(7):842-55. PubMed ID: 7321343
    [No Abstract]   [Full Text] [Related]  

  • 35. Intracrystalline proteins and urolithiasis: a synchrotron X-ray diffraction study of calcium oxalate monohydrate.
    Fleming DE; Van Riessen A; Chauvet MC; Grover PK; Hunter B; van Bronswijk W; Ryall RL
    J Bone Miner Res; 2003 Jul; 18(7):1282-91. PubMed ID: 12854839
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inter-alpha-inhibitor: a protein family involved in the inhibition of calcium oxalate crystallization.
    Atmani F; Mizon J; Khan SR
    Scanning Microsc; 1996; 10(2):425-33; discussion 433-4. PubMed ID: 9813621
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hydrogen exchane at the beta-carbon of amino acids during transamination.
    Walter U; Luthe H; Söling HD
    Eur J Biochem; 1975 Nov; 59(2):395-403. PubMed ID: 1204622
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of citrate on the different phases of calcium oxalate crystallization.
    Tiselius HG; Berg C; Fornander AM; Nilsson MA
    Scanning Microsc; 1993 Mar; 7(1):381-9; discussion 389-90. PubMed ID: 8316807
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alendronate inhibits urinary calcium microlith formation in a three-dimensional culture model.
    Senzaki H; Yasui T; Okada A; Ito Y; Tozawa K; Kohri K
    Urol Res; 2004 Jun; 32(3):223-8. PubMed ID: 15064876
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Idiopathic recurrent calcium urolithiasis (IRCU): an acid meal challenge uncovers inappropriate pH of postprandial, fasting and daily urine: a cross-sectional study of male patients providing insight into post- and pre-load urinary stone substances, crystallization risk, presence of stones, renal transport and systemic metabolic factors.
    Schwille PO; Wipplinger J
    Eur J Med Res; 2008 Jul; 13(7):332-42. PubMed ID: 18700191
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.